COMPASS Pathways plc

NASDAQ:CMPS

Medical - Care Facilities

Healthcare
$8.12 +0.16%

+$0.02 today

Market cap
$1.15B
Beta
2.51
P/E (TTM)
-7.4
EPS (TTM)
-$1.63
52W Low $2.25High $14.76

Volume 2.35M

Average 4.09M

CMPS Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

COMPASS Pathways plcNASDAQ: CMPS

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash grows, but more slowly than its trailing trend

Q1 FY2026 net change in cash of $316.4M rose 233.0% year over year, behind the +7485.2% change in trailing-twelve-month net change in cash. Over 3 fiscal years it compounded at -50.8% a year.

Context

  • Net change in cash increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +233.0% toward the trailing-twelve-month pace of +7485.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$316.4M+970.9% QoQ
Last fiscal yearDec 2025
-$15.48M-71.9% YoY
LTMMar 2026
$205.9M+7485.2% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+233.0%——
1 year-71.9%——
3-year CAGR-50.8%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(15.48M) USD
Year-over-year change
+71.9%

Net Change in Cash vs competitors

How CMPS compares with its peers on the latest reported figures

  • CMPS's LTM Mar 2026 net change in cash of $205.9M is the 6th largest of the 11 companies compared; the peer median is $40.39M.
  • Its year-over-year change of +7485.2% is the highest of 9, against a peer median of +142.3%.
  • Over three fiscal years its annual growth of -50.8% compares with a peer median of +93.4%.
CMPS Competitors Peer median
Net Change in Cash for CMPS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NERVMinerva Neurosciences, Inc.LTM Jun 2026$57.58B ———
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$300.86M —+123.5%—
ACADACADIA Pharmaceuticals Inc.LTM Jun 2026$235.87M +194.1%+63.3%20.7%
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$221.19M +180.3%——
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$210.79M +1202.6%——
CMPSCOMPASS Pathways plcLTM Mar 2026$205.9M +7485.2%-50.8%—
DNLIDenali Therapeutics Inc.LTM Jun 2026$60.32M -11.4%—1673.8%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$20.45M +222.7%—102.3%
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$5.55M +104.3%-32.6%—
HRMYHarmony Biosciences Holdings, Inc.LTM Jun 2026$3.72M -98.4%+216.2%0.4%
GHRSGH Research PLCLTM Mar 2026$2.3M -101.4%——
Peer median (excluding CMPS) $40.39M+142.3%+93.4%61.5%

Competitors are the stored peer set for CMPS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.74M)(91.51M)(118.46M)(155.12M)(287.86M)
Depreciation & Amortization175K330K242K233K216K
Deferred Income Tax22K0000
Stock-Based Compensation8.64M13.12M17.28M19.52M13.59M
Change in Working Capital(6.64M)(30.67M)3.48M11.72M(14.28M)
Accounts Receivables00000
Inventory00000
Accounts Payables(163K)2.5M864K6.59M2.03M
Other Working Capital(6.47M)(33.16M)2.62M5.13M(16.32M)
Other Non-Cash Items1.8M3.27M86K4.46M131.1M
Operating Cash Flow(67.75M)(105.45M)(97.38M)(119.19M)(157.24M)
Capital Expenditures(334K)(596K)(66K)00
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities002K00
Investing Cash Flow(334K)(596K)(64K)00
Debt Repayment0029.59M00
Common Stock Issued154.79M440K144.94M26.22M141.04M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.85M600K(690K)37.61M(328.83K)
Financing Cash Flow156.65M1.04M173.83M63.82M140.71M
Effect of Forex Changes(5.58M)(24.96M)867K194K1.05M
Net Change in Cash82.99M(129.97M)77.26M(55.17M)(15.48M)
Free Cash Flow(68.08M)(106.05M)(97.44M)(119.19M)(157.24M)

COMPASS Pathways plc

NASDAQ:CMPS

Intrinsic Alpha fair value

Locked

Current Price

$8.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.